亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

塞鲁美替尼 医学 多西紫杉醇 克拉斯 安慰剂 内科学 肺癌 肿瘤科 MEK抑制剂 随机对照试验 癌症 结直肠癌 MAPK/ERK通路 病理 激酶 替代医学 细胞生物学 生物
作者
Pasi A. Jänne,Alice T. Shaw,José Rodrigues Pereira,G. Jeannin,Johan Vansteenkiste,Carlos H. Barrios,Fábio Franke,Lynda Grinsted,Victoria Zazulina,Paul D. Smith,Ian C. P. Smith,Lucio Crinò
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:14 (1): 38-47 被引量:645
标识
DOI:10.1016/s1470-2045(12)70489-8
摘要

No targeted therapies are available for KRAS-mutant non-small-cell lung cancer (NSCLC). Selumetinib is an inhibitor of MEK1/MEK2, downstream of KRAS, with preclinical evidence of synergistic activity with docetaxel in KRAS-mutant cancers. We did a prospective, randomised, phase 2 trial to assess selumetinib plus docetaxel in previously treated patients with advanced KRAS-mutant NSCLC.Eligible patients were older than 18 years of age; had histologically or cytologically confirmed stage IIIB-IV KRAS-mutant NSCLC; had failed first-line therapy for advanced NSCLC; had WHO performance status of 0-1; had not received previous therapy with either a MEK inhibitor or docetaxel; and had adequate bone marrow, renal, and liver function. Patients were randomly assigned (in a 1:1 ratio) to either oral selumetinib (75 mg twice daily in a 21 day cycle) or placebo; all patients received intravenous docetaxel (75 mg/m(2) on day 1 of a 21 day cycle). Randomisation was done with an interactive voice response system and investigators, patients, data analysts, and the trial sponsor were masked to treatment assignment. The primary endpoint was overall survival, analysed for all patients with confirmed KRAS mutations. This study is registered with ClinicalTrials.gov, number NCT00890825.Between April 20, 2009, and June 30, 2010, we randomly assigned 44 patients to receive selumetinib and docetaxel (selumetinib group) and 43 to receive placebo and docetaxel (placebo group). Of these, one patient in the selumetinib group and three in the placebo group were excluded from efficacy analyses because their tumours were not confirmed to be KRAS-mutation positive. Median overall survival was 9·4 months (6·8-13·6) in the selumetinib group and 5·2 months (95% CI 3·8-non-calculable) in the placebo group (hazard ratio [HR] for death 0·80, 80% CI 0·56-1·14; one-sided p=0·21). Median progression-free survival was 5·3 months (4·6-6·4) in the selumetinib group and 2·1 months (95% CI 1·4-3·7) in the placebo group (HR for progression 0·58, 80% CI 0·42-0·79; one-sided p=0·014). 16 (37%) patients in the selumetinib group and none in the placebo group had an objective response (p<0·0001). Adverse events of grade 3 or higher occurred in 36 (82%) patients in the selumetinib group and 28 (67%) patients in the placebo group. The most common grade 3-4 adverse events were neutropenia (29 [67%] of 43 patients in the selumetinib group vs 23 [55%] of 42 patients in the placebo group), febrile neutropenia (eight [18%] of 44 patients in the selumetinib group vs none in the placebo group), dyspnoea (one [2%] of 44 patients in the selumetinib group vs five [12%] of 42 in the placebo group), and asthenia (four [9%] of 44 patients in the selumetinib group vs none in the placebo group).Selumetinib plus docetaxel has promising efficacy, albeit with a higher number of adverse events than with docetaxel alone, in previously treated advanced KRAS-mutant NSCLC. These findings warrant further clinical investigation of selumetinib plus docetaxel in KRAS-mutant NSCLC.AstraZeneca.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
22秒前
残月初升完成签到,获得积分10
24秒前
顺心的一德完成签到,获得积分10
31秒前
阔达之卉完成签到 ,获得积分10
36秒前
虚幻的霸完成签到,获得积分10
38秒前
flyingpig发布了新的文献求助30
42秒前
51秒前
zeng发布了新的文献求助10
57秒前
冷傲的夜白完成签到,获得积分10
1分钟前
汉堡包的应助被ADAB0002采纳,获得10
1分钟前
奔跑的应助被zeng采纳,获得10
1分钟前
飞快的涵柳完成签到,获得积分10
1分钟前
1分钟前
1分钟前
愤怒的若颜完成签到,获得积分10
1分钟前
可言完成签到,获得积分10
1分钟前
SUNny发布了新的文献求助10
1分钟前
zsmj23完成签到 ,获得积分0
1分钟前
1分钟前
科目三的应助被SUNny采纳,获得10
2分钟前
思源的应助被杨佳佳采纳,获得10
2分钟前
madeleinli的应助被flyingpig采纳,获得10
2分钟前
伶俐的万言完成签到,获得积分10
2分钟前
8旬老太快乐读研完成签到 ,获得积分10
2分钟前
安静白柏完成签到,获得积分10
2分钟前
nk完成签到 ,获得积分10
2分钟前
矮小的幼晴完成签到,获得积分10
2分钟前
ADAB0002发布了新的文献求助10
3分钟前
SciGPT的应助被科研通管家采纳,获得10
3分钟前
3分钟前
null的应助被科研通管家采纳,获得10
3分钟前
3分钟前
3分钟前
3分钟前
ADAB0002发布了新的文献求助10
3分钟前
3分钟前
失眠的热狗完成签到,获得积分10
3分钟前
Haoyu发布了新的文献求助10
3分钟前
阳光灭绝完成签到,获得积分10
3分钟前
ADAB0002发布了新的文献求助10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166106
求助须知:如何正确求助?哪些是违规求助? 9559433
关于积分的说明 21750245
捐赠科研通 7756975
什么是DOI,文献DOI怎么找? 3429113
关于科研通互助平台的介绍 2553436
邀请新用户注册赠送积分活动 2473781